主动监测碳青霉烯类耐药菌对ICU医疗保健相关感染及临床预后的影响:倾向性评分匹配的历史队列研究
该研究为前瞻性干预研究加事后回顾性历史对照队列设计,纳入宁夏医科大学总医院ICU 2024年(常规检测组690例)与2025年(CRO主动监测组608例)住院患者,主动监测于入ICU 24小时内采集鼻拭子、直肠拭子、痰及伤口/引流分泌物接种显色培养基,阳性者接触隔离。CRO主动监测组阳性率22.4%(142/634)。倾向性评分1:1匹配后各477对,两组CRO医院感染发生率无统计学差异(2.3% vs. 2.5%,P>0.05),但主动监测组ICU死亡率(2.1% vs. 4.6%)、治疗放弃率(8.6% vs. 18.0%)显著降低,好转出院率(89.3% vs. 77.4%)显著提高(均P<0.05)。
要点
- 在基础感染防控完善的ICU,CRO主动监测联合接触隔离未进一步降低CRO医院感染发生率(2.3% vs. 2.5%,P>0.05)。
- CRO主动监测使ICU死亡率从4.6%降至2.1%、治疗放弃率从18.0%降至8.6%、好转出院率从77.4%升至89.3%(均P<0.05)。
- 主动监测于入ICU 24小时内采集鼻拭子、直肠拭子、痰及伤口/引流分泌物接种显色培养基,阳性率22.4%(142/634)。
- CRO阳性者采取接触隔离,阴性者继续标准预防;主动监测通过早期预警和指导精准抗菌治疗改善预后。
适用人群与场景
- 宁夏医科大学总医院ICU住院患者,2024年1月1日至12月31日入院者为常规检测组(690例),2025年1月1日至12月31日入院者为CRO主动监测组(608例符合纳入标准)。
- CRO主动监测组于入ICU 24小时内接受主动监测;排除人群原文未提及。
诊断标准与关键阈值
- CRO主动监测方案:入ICU 24小时内采集鼻拭子、直肠拭子、痰标本及现有伤口或引流部位的分泌物/引流液,接种于显色培养基。
- CRO结果阳性者视为CRO定植或感染并实施接触隔离;阴性者继续标准预防。
处置流程与药物剂量
- 第一步:入ICU 24小时内采集鼻拭子、直肠拭子、痰标本及伤口/引流分泌物或引流液,接种显色培养基进行CRO主动监测。
- 第二步:CRO阳性者实施接触隔离;阴性者继续标准预防。
- 第三步:基于主动监测结果进行早期预警并指导精准抗菌治疗(原文未提及具体药物、剂量及疗程)。
红旗征与不能漏的情况
- 原文未提及
研究设计与关键结果
- 倾向性评分匹配(1:1,卡钳值0.02)控制年龄、性别、APACHE II评分、手术创伤严重程度(手术分级×手术次数)及机械通气、中心静脉置管、导尿管留置时间后,成功匹配477对,基线均衡(所有SMD<0.1,所有P>0.05)。
- 主要终点:匹配后CRO医院感染发生率主动监测组2.3%(11/477)vs. 常规检测组2.5%(12/477),无统计学差异(均P>0.05)。
- 关键次要终点:ICU死亡率2.1%(10/477)vs. 4.6%(22/477),治疗放弃率8.6%(41/477)vs. 18.0%(86/477),好转出院率89.3%(426/477)vs. 77.4%(369/477),均P<0.05。
- 不良事件:原文未提及。
证据类型、等级与局限
- 证据类型:单中心前瞻性干预研究加事后回顾性历史对照队列设计;原文未给出证据等级或推荐强度。
- 局限:单中心、历史对照设计、非随机分组,虽经倾向性评分匹配控制混杂,仍可能存在未测量混杂;原文未提及其他局限。
对床旁实践的改变
- 在基础感染防控措施已完善的ICU,实施CRO主动监测联合接触隔离不能进一步降低CRO医院感染发生率,不应期待该措施降低感染率。
- CRO主动监测可通过早期预警和指导精准抗菌治疗改善患者预后(降低ICU死亡率、治疗放弃率,提高好转出院率),支持在ICU开展主动监测。
- 主动监测方案为入ICU 24小时内采集鼻拭子、直肠拭子、痰及伤口/引流分泌物接种显色培养基,阳性者接触隔离、阴性者标准预防。
- 适用与不适用人群:原文未明确排除人群;结论来自基础感染防控完善的单中心ICU,外推需谨慎。
指南或共识出处
- 原文未提及
以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVE: To evaluate the impact of active surveillance for carbapenem-resistant organisms (CRO) on healthcare-associated infections and clinical prognosis of patients in intensive care unit (ICU), and to provide real-world clinical evidence for developing scientific CRO active surveillance protocols in medical institutions.
METHODS: A prospective intervention study with a post-hoc retrospective historical control cohort design was conducted. ICU inpatients at the General Hospital of Ningxia Medical University from January 1, 2024 to December 31, 2025 were enrolled. The routine testing group comprised patients hospitalized from January 1 to December 31, 2024, who underwent routine microbiological testing with only retrospective chart review (690 cases). The CRO active surveillance group comprised patients hospitalized from January 1 to December 31, 2025, who received active CRO surveillance within 24 hours of ICU admission (608 cases). The active surveillance protocol involved collecting nasal swabs, rectal swabs, sputum specimens, and secretions or drainage fluids from existing wounds or drainage sites, which were inoculated onto chromogenic media. Patients with positive CRO results were considered colonized or infected with CRO and placed under contact precautions; those with negative results continued to receive standard precautions. Propensity score matching (PSM) at a 1 : 1 ratio was used to control for confounding factors including age, sex, acute physiology and chronic health evaluation II(APACHE II), severity of surgical insult (surgical grade×number of surgeries), and durations of mechanical ventilation, central venous catheterization, and urinary catheterization, with a caliper value of 0.02. After matching, the two groups were compared for CRO healthcare-associated infection incidence and clinical outcomes (in-ICU mortality, treatment abandonment rate, and improvement-to-discharge rate).
RESULTS: A total of 634 patients in the CRO active surveillance group underwent active surveillance (608 of whom met inclusion criteria), with a CRO positivity rate of 22.4% (142/634). A total of 1 298 patients were enrolled, including 690 in the routine testing group and 608 in the CRO active surveillance group. After PSM, 477 pairs were successfully matched, with 477 cases in the routine testing group and 477 cases in the CRO active surveillance group. After matching, baseline characteristics were well balanced and comparable between the two groups [all standardized mean differences (SMD)<0.1, all P>0.05]. After PSM, there was no statistically significant difference in CRO nosocomial infection incidence between the CRO active surveillance group and the routine testing group [2.3% (11/477) vs. 2.5% (12/477), both P>0.05]. However, the CRO active surveillance group had significantly lower in-ICU mortality [2.1% (10/477) vs. 4.6% (22/477)] and treatment abandonment rate [8.6% (41/477) vs. 18.0% (86/477)] compared with the routine testing group (both P<0.05), and a significantly higher improvement-to-discharge rate [89.3% (426/477) vs. 77.4% (369/477), both P<0.05].
CONCLUSIONS: In ICUs with well-established basic infection prevention and control measures, implementation of CRO active surveillance combined with contact isolation did not further reduce the incidence of CRO healthcare-associated infections. However, it significantly improved patient outcomes by enabling early warning and guiding precise antimicrobial therapy.
参考来源
- Kou H, Li X, Geng Y, et al. [Impact of active surveillance for carbapenem-resistant organisms on healthcare-associated infections and clinical prognosis of patients in intensive care unit: a propensity score-matching historical cohort study]. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2026. PMID: 42875236. doi:10.3760/cma.j.cn121430-20260605-00271
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。